semaglutide uses and side effects Semaglutide: Double-edged Sword with Risks Benefits Ozempic vs. Wegovy vs. Mounjaro:

The semaglutide group experienced fewer serious adverse events compared to placebo ( 49.6% versus 53.8%), but more adverse events leading to discontinuation ( 13.2% versus 11.9%)

What the Research Says: Key Studies Large-Scale Safety Data The STEP clinical trial program enrolled over 4,500 participants across multiple studies and did not identify hypothyroidism as a safety signal or adverse event of concern

Rapid heartbeat or fast breathing: These are signs of urgent problems that require hospital care

Safety: GI events remain the class effect

While generally safe, certain individuals should avoid AOD-9604, including: Pregnant or breastfeeding women Due to limited safety data